市場調査レポート

商品コード

1800829

ぶどう膜炎治療薬市場の分析：治療薬の種類別、疾患の種類別、病因別、流通チャネル別、地域別（2025～2033年）

Uveitis Treatment Market Report by Treatment Type, Disease Type, Cause, Distribution Channel, and Region 2025-2033

出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 150 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 444,961円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (5 User License)

USD 3,999 593,331円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストはできませんが、印刷は5部まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 741,701円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストは可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.37円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のぶどう膜炎治療薬の市場規模は2024年に18億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに27億米ドルに達し、2025～2033年の成長率（CAGR）は4.44％になると予測しています。同市場は、ぶどう膜炎の罹患率の上昇、治療の可能性を多様化するためのさまざまな生物製剤や免疫抑制治療における研究開発の進行、認知度の向上と早期診断の重視の高まり、有利な政府政策、医療費償還によって大きな成長を遂げています。

ぶどう膜炎治療薬市場の動向：

自己免疫疾患の増加

ぶどう膜炎治療薬の需要は、世界中で増加している自己免疫疾患によって刺激されています。米国国立衛生研究所（NIH）の報告によると、自己免疫疾患は2,350万人の米国人が罹患していると推定されており、関節リウマチ、炎症性腸疾患、狼瘡などが後遺症としてぶどう膜炎を発症しています。この有病率は、自己免疫疾患をターゲットとした効率的なぶどう膜炎治療薬への高い要求を証明し、市場の需要を刺激していることに注意することが重要です。このように、これらの疾患は世界中で高い頻度で発生しているため、ぶどう膜炎とその治療法は症状をコントロールすることを目的としており、患者の生活により良い結果をもたらすために、疾患の原因となる自己免疫プロセスに対処するものです。

生物製剤と免疫療法の進歩

生物学的製剤と免疫調節療法は免疫介在プロセスを調節することによりぶどう膜炎管理に革命をもたらしました。米国国立衛生研究所（NIH）はぶどう膜炎などの自己免疫疾患に対して様々な生物学的製剤を承認しており、これは費用対効果が高く効果的な生物学的製剤の使用への変化を示しています。このような治療法には、副腎皮質ステロイドのような他の治療法よりも、体内の他の臓器に影響を及ぼす副作用の可能性が低いなどの利点があり、その結果、患者は推奨された治療レジメンに従うようになっています。その結果、バイオテクノロジーと免疫学の市場開拓が進み、生物学的製剤と免疫調節剤の製品開発が進み、世界市場におけるぶどう膜炎治療の機会が拡大しています。

医療支出と研究資金の増加

医療システムへの政府支出の増加、開発戦略、医療の進歩がぶどう膜炎治療薬の市場価値を高めています。米国では、ぶどう膜炎やその他の自己免疫疾患の調査にNIHが多額の資金を支援しており、この調査は大学、製薬業界、病院などの多部門・多機関の協力によって行われています。この資金援助は、新薬、生物製剤、治療法の開発を後押しし、ぶどう膜炎の新たな治療法の進展にさらに良い変化をもたらしています。さらに、政府によって支援されている研究助成金や臨床試験は、新規治療プロファイルの探索を支援し、治療の有効性を検証するために不可欠な枠組みやリソースを提供しています。このような力学により、市場力学は研究集約型となっており、発見を臨床的に有用な製品やサービスに変換することで、世界中の既存の要件に対応し、患者体験を向上させています。

北米
- 米国
- カナダ
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ

第11章 SWOT分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- AbbVie Inc.
- Alimera Sciences Inc.
- Bausch & Lomb Incorporated（Bausch Health）
- Enzo Biochem Inc.
- Eyegate Pharmaceuticals Inc.
- Eyepoint pharmaceuticals Inc.
- Novartis AG
- Regeneron Pharmaceuticals Inc
- Santen Pharmaceutical Co. Ltd.

図表

List of Figures

Figure 1: Global: Uveitis Treatment Market: Major Drivers and Challenges
Figure 2: Global: Uveitis Treatment Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Uveitis Treatment Market: Breakup by Treatment Type (in %), 2024
Figure 4: Global: Uveitis Treatment Market: Breakup by Disease Type (in %), 2024
Figure 5: Global: Uveitis Treatment Market: Breakup by Cause (in %), 2024
Figure 6: Global: Uveitis Treatment Market: Breakup by Distribution Channel (in %), 2024
Figure 7: Global: Uveitis Treatment Market: Breakup by Region (in %), 2024
Figure 8: Global: Uveitis Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 9: Global: Uveitis Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Uveitis Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Uveitis Treatment (Immunosuppressant) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Uveitis Treatment (Immunosuppressant) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Uveitis Treatment (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Uveitis Treatment (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Uveitis Treatment (Cycloplegic Agents) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Uveitis Treatment (Cycloplegic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Uveitis Treatment (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Uveitis Treatment (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Uveitis Treatment (Antivirals) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Uveitis Treatment (Antivirals) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Uveitis Treatment (Antifungal) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Uveitis Treatment (Antifungal) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Uveitis Treatment (Analgesics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Uveitis Treatment (Analgesics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Uveitis Treatment (Anterior Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Uveitis Treatment (Anterior Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Uveitis Treatment (Posterior Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Uveitis Treatment (Posterior Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Uveitis Treatment (Intermediate Uveitis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Uveitis Treatment (Intermediate Uveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Global: Uveitis Treatment (Panuveitis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Global: Uveitis Treatment (Panuveitis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: Global: Uveitis Treatment (Infectious) Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: Global: Uveitis Treatment (Infectious) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Global: Uveitis Treatment (Non-infectious) Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Global: Uveitis Treatment (Non-infectious) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Global: Uveitis Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Global: Uveitis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: Global: Uveitis Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: Global: Uveitis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Global: Uveitis Treatment (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Global: Uveitis Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: Global: Uveitis Treatment (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: Global: Uveitis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: North America: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: North America: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: United States: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: United States: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Canada: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Canada: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Asia Pacific: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Asia Pacific: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: China: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: China: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Japan: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Japan: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: India: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: India: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: South Korea: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: South Korea: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Australia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Australia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Indonesia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Indonesia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Europe: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Europe: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Germany: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Germany: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: France: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: France: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: United Kingdom: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: United Kingdom: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Italy: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Italy: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Spain: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Spain: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Russia: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 80: Russia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 81: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 82: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 83: Latin America: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 84: Latin America: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 85: Brazil: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 86: Brazil: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 87: Mexico: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 88: Mexico: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 89: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 90: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 91: Middle East and Africa: Uveitis Treatment Market: Sales Value (in Million USD), 2019 & 2024
Figure 92: Middle East and Africa: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 93: Global: Uveitis Treatment Industry: SWOT Analysis
Figure 94: Global: Uveitis Treatment Industry: Value Chain Analysis
Figure 95: Global: Uveitis Treatment Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Uveitis Treatment Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Uveitis Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
Table 3: Global: Uveitis Treatment Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
Table 4: Global: Uveitis Treatment Market Forecast: Breakup by Cause (in Million USD), 2025-2033
Table 5: Global: Uveitis Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 6: Global: Uveitis Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Uveitis Treatment Market Structure
Table 8: Global: Uveitis Treatment Market: Key Players

Product Code: SR112025A2759

The global uveitis treatment market size reached USD 1.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.44% during 2025-2033. The market is experiencing significant growth driven by the rising incidence of uveitis, ongoing research and development activities in various biologics and immunosuppressive treatments to diversify treatment possibilities, heightening emphasis on increasing awareness and early diagnosis, favorable government policies, and healthcare reimbursements.

Uveitis Treatment Market Trends:

Increasing Prevalence of Autoimmune Diseases

The uveitis treatment demand is stimulated by the increased rate of autoimmune diseases all over the world. As reported by the National Institutes of Health (NIH), autoimmune diseases are estimated to affect 23.5 million Americans, who have rheumatoid arthritis, inflammatory bowel disease, and lupus among other diseases develop uveitis as a sequel. It is important to note that this prevalence proves the high requirement for efficient uveitis therapies targeted at autoimmune diseases and stimulating the demand in the market. Thus, as these diseases move high across the world, treatment aims for uveitis and its therapies controlling the symptoms and it addresses the autoimmune processes that cause the disease to achieve better results in patients' lives.

Advancements in Biologics and Immunotherapy Therapies

Biologics and immunomodulatory therapies have revolutionized uveitis management by modulation of immune-mediated processes. The National Institutes of Health (NIH) has approved various biologics for autoimmune diseases, such as uveitis, signifying the change towards the use of cost-effective and effective biologics. Such therapies have benefits such as lower probability of side effects affecting other organs in the body than other treatments like corticosteroids which in turn is witnessing patients being more compliant to the treatment regimens that are recommended to them. As a result, there are continued markets in biotechnology and immunology leading to product development in biologics and immunomodulators extending the opportunities for the treatment of uveitis in the global market.

Rising Healthcare Expenditure and Research Funding

Increased government spending in healthcare systems, development strategies, and advances in healthcare are fueling the uveitis treatment market value. In the USA, the NIH supports significant funding to investigate uveitis and other auto-immune disorders, and this research has been a multisectoral and multiparty cooperation among universities, pharmaceutical industries, and hospitals. This financial support further brings a positive change to the progression of new treatments for uveitis as it pushes the development of new drugs, biologics, and treatment methods. Moreover, research grants and clinical trials that are supported by the government offer essential frameworks and resources to support the exploration of novel therapeutic profiles and verify the effectiveness of treatments. These dynamics make the uveitis treatment market highly research-intensive, as it capitalizes on the conversion of discoveries into clinically useful products and services that address existing requirements and enhance patient experience worldwide.

Uveitis Treatment Market Segmentation:

Breakup by Treatment Type:

Corticosteroids
Immunosuppressant
Monoclonal Antibodies
Cycloplegic Agents
Antibiotics
Antivirals
Antifungal
Analgesics

Corticosteroids account for the majority of the market share

As per the uveitis treatment market forecast, Corticosteroids thus dominate the uveitis treatment market by share since they help reduce inflammation and maintain vision in affected individuals. The National Institutes of Health (NIH) reported that corticosteroids are the primary therapy for uveitis, as they yield fast control of inflammation and signs about different uveitis types, anterior, posterior, and panuveitis. The main indications for these medicines are to lessen the body's ability to fight infection in the eye and diminish inflammation, which provides fast and effective relief and enhances the degree of patient's health. Corticosteroids can be administered through eye drops, injections, and oral tablets depending on the intensity of the situation and condition of the patient. As corticosteroids present possible side-effects, including rising intraocular pressure and postoperative cataract formation by long-term application, they remain preferred to other competitors while moderately effective topical NSAIDs are not as popular in uveitis treatment despite frequent use in ophthalmological practice.

Breakup by Disease Type:

Anterior Uveitis
Posterior Uveitis
Intermediate Uveitis
Panuveitis

Anterior uveitis holds the largest share of the industry

Anterior uveitis holds a leading position in the segmentation of uveitis treatment because of its greater incidence and the necessity of unique therapy. The National Institutes of Health (NIH) categorizes anterior uveitis as the most prevalent type of uveitis which accounts for 50-60% of all uveitis reported in the United States. This is caused by inflammation of the structures of the anterior part of the eye known as the uvea, it is linked with autoimmune diseases, infections, or physical injury. As a result, the pattern implies the treatment of anterior uveitis requires different management strategies such as topical corticosteroids and pupil-dilating agents available, routinely managed in clinics or ophthalmology and retail outlets, thus creating a favorable

Breakup by Cause:

Infectious
Non-infectious

Non-infectious represents the leading market segment

Non-infectious drive the uveitis treatment market revenue as the condition is more frequent than the infection-related kind and was addressed using improving evidence-based individualized treatment targeting autoimmune and inflammation processes. According to the National Institutes of Health (NIH), non-infectious uveitis accounts for approximately 80-90% of all uveitis cases in the United States. This form of uveitis is more related to autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, lupus, and the need for biologics and immunomodulatory agents. It has been observed by researchers from across the world that the cases of autoimmune diseases are continuously increasing, which strengthens the market position of the non-infectious forms of uveitis treatments. The modern pharmaceutical industry concentrates on the development of proper individual antiretirologic preparations to target more effectively the immunopathogenetic background of non-infectious uveitis with minimal side effects from systemic administration, thus creating a favorable uveitis treatment market outlook.

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Retail pharmacies exhibit a clear dominance in the market

Retail pharmacies hold the largest market share of uveitis treatment primarily because they are easily accessible, and convenient, especially to the patients and they also engage in the dispensing of drugs. The National Community Pharmacists Association (NCPA) repoted that retail pharmacies in the United States dispense about 72% of prescriptions emphasizing the centrality of pharmacists in dispensing of medication. This uveitis treatment market overview shows that patients diagnosed with uveitis can conveniently get prescribed medicines such as corticosteroid, immunosuppressant, and biologic agents from the retail pharmacy at a faster pace. Additionally, retail pharmacies involve patient counseling, medication and health insurance information and management, which improves patient satisfaction and outcomes. Stakeholders use them to interface with the health systems and electronic health records, thereby providing continuity of care to patients with uveitis. Due to increased diversification of services and sophisticated patient and consumer focus in retail pharmacy, they significantly contribute to meeting the increasing needs of the market for uveitis medications and dominating the distribution of drugs.

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America leads the market, accounting for the largest uveitis treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil Mexico, and others) and the Middle East and Africa. According to the report, North America was the largest regional market for uveitis treatment.

As per the uveitis treatment market report, North America holds the largest market share due to its well-developed and advanced healthcare sector, acceptance of novel therapeutic management, and direct spending on research and development. As reported by the National Institutes of Health (NIH), a significant budget is devoted to autoimmune disease studies in the United States alone and there exists a conducive environment for numerous clinical trials and partnerships among various pharmaceutical entities, research institutions, and caregivers. Such strategic investment allows North American countries to take a frontline in the development and commercialization of biologics, immunomodulatory, and other approaches to treating uveitis. Also, presenting a higher frequency of autoimmune diseases which later develop into uveitis, the North American region needs efficient uveitis treatment and management, thereby carrying the market leadership of the global uveitis market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the uveitis treatment industry include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Santen Pharmaceutical Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The uveitis treatment companies are focusing on the development of uveitis treatment include pharmaceutical companies and research institutions to meet the various challenges presented by the uveitis disease process through clinical trials. The market leaders such as AbbVie, Novartis, and Allergan are committed to research and development to launch new drugs that address specific immunological processes of uveitis development. For instance, the research strategies of AbbVie involve recent collaborations and clinical trials that explore the usage of biologics for autoimmune uveitis, proving the focus on precision medicine. Many of these activities are funded through government and research grants that promote academic-industry collaboration to advance therapeutic progress and improve patients' care in the context of the shifting uveitis treatment paradigm, thus fueling uveitis treatment industry growth.

Key Questions Answered in This Report

1.What was the size of the global uveitis treatment market in 2024?
2.What is the expected growth rate of the global uveitis treatment market during 2025-2033?
3.What has been the impact of COVID-19 on the global uveitis treatment market?
4.What are the key factors driving the global uveitis treatment market?
5.What is the breakup of the global uveitis treatment market based on the treatment type?
6.What is the breakup of the global uveitis treatment market based on the disease type?
7.What is the breakup of the global uveitis treatment market based on the cause?
8.What is the breakup of the global uveitis treatment market based on the distribution channel?
9.What are the key regions in the global uveitis treatment market?
10.Who are the key players/companies in the global uveitis treatment market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Uveitis Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Treatment Type

6.1 Corticosteroids
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Immunosuppressant
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Monoclonal Antibodies
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Cycloplegic Agents
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Antibiotics
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Antivirals
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 Antifungal
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
6.8 Analgesics
- 6.8.1 Market Trends
- 6.8.2 Market Forecast

7 Market Breakup by Disease Type

7.1 Anterior Uveitis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Posterior Uveitis
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Intermediate Uveitis
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Panuveitis
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Cause

8.1 Infectious
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Non-infectious
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Alimera Sciences Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
- 15.3.3 Bausch & Lomb Incorporated (Bausch Health)
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 SWOT Analysis
- 15.3.4 Enzo Biochem Inc.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Eyegate Pharmaceuticals Inc.
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
- 15.3.6 Eyepoint pharmaceuticals Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
- 15.3.7 Novartis AG
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Regeneron Pharmaceuticals Inc
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Santen Pharmaceutical Co. Ltd.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis

ぶどう膜炎治療薬市場の分析：治療薬の種類別、疾患の種類別、病因別、流通チャネル別、地域別（2025～2033年）

Uveitis Treatment Market Report by Treatment Type, Disease Type, Cause, Distribution Channel, and Region 2025-2033

ぶどう膜炎治療薬市場の動向：

目次

第1章 序文

第2章 分析範囲・手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のぶどう膜炎治療薬市場

第6章 市場区分：治療薬の種類別

第7章 市場区分：疾患の種類別

第8章 市場区分：病因別

第9章 市場区分：流通チャネル別

第10章 市場区分：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢